Abstract:Abstract Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies. However, CAR immunotherapy in solid tumors lags significantly behind. Some of the major hurdles for CAR immunotherapy in solid tumors include CAR T cell manufacturing, lack of tumor-specific antigens, inefficient CAR T cell trafficking and infiltration into tumor sites, immunosuppressive tumor microenvironment (TME), therapy-associated toxicity, and antigen escape. CAR Natural Killer (NK) cells have several advantages over CAR T cells as the NK cells can be manufactured from pre-existing cell lines or allogeneic NK cells with unmatched major histocompatibility complex (MHC); can kill cancer cells through both CAR-dependent and CAR-independent pathways; and have less toxicity, especially cytokine-release syndrome and neurotoxicity. At least one clinical trial showed the efficacy and tolerability of CAR NK cell therapy. Macrophages can efficiently infiltrate into tumors, are major immune regulators and abundantly present in TME. The immunosuppressive M2 macrophages are at least as efficient as the proinflammatory M1 macrophages in phagocytosis of target cells; and M2 macrophages can be induced to differentiate to the M1 phenotype. Consequently, there is significant interest in developing CAR macrophages for cancer immunotherapy to overcome some major hurdles associated with CAR T/NK therapy, especially in solid tumors. Nevertheless, both CAR NK and CAR macrophages have their own limitations. This comprehensive review article will discuss the current status and the major hurdles associated with CAR T and CAR NK therapy, followed by the structure and cutting-edge research of developing CAR macrophages as cancer-specific phagocytes, antigen presenters, immunostimulators, and TME modifiers.

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review)

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond

Recent advances and progress in immunotherapy of solid cancers

CAR-macrophage Versus CAR-T for Solid Tumors: the Race Between a Rising Star and a Superstar.

Recent Advances in CAR-Based Solid Tumor Immunotherapy

Current Progress in Chimeric Antigen Receptor T‐cell Therapy for Malignant Tumors

Research Advances in Chimeric Antigen Receptor-Modified T-cell Therapy (Review)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors